OPK · XBRL financial data

OPKO Health financial statements, every quarter

The same tables from 14 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (OPK's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	179	182	174	182	174	184	150	157	152	148	124	164
Cost of goods and services sold	—	year only	132	131	134	99*	107	107	102	84*	78	84
Gross profit	—	year only	42	52	40	85*	43	49	50	64*	46	80
Research and development	19	19*	22	24	29	30*	31	30	30	33*	29	33
Selling, general and administrative	72	73*	70	69	98	67*	59	60	54	51*	49	53
Total operating expenses	243	251	245	244	159	217	217	217	104	187	—	—
Operating income (loss)	(64)	(69)*	(71)	(62)	14	(33)*	(67)	(60)	48	(38)*	(51)	(7)
Interest income	1	1*	1	0	3	4*	5	3	3	4*	3	3
Interest expense	3	3*	8	8	17	14*	15	70	11	11*	11	11
Other income (expense)	(12)	(1)*	21	59	49	78*	5	(36)	2	(1)*	(2)	2
Income tax expense (benefit)	6	(6)*	(1)	(0)	24	21*	(6)	(14)	20	(16)*	(6)	(5)
Net income (loss)	(84)	(66)	(82)	(10)	25	14	(68)	(148)	22	(31)	(55)	(8)
Earnings per share, basic USD per share	(0.11)	(0.09)	(0.12)	(0.01)	0.04	0.02	(0.10)	(0.19)	0.03	(0.04)	(0.07)	(0.01)
Earnings per share, diluted USD per share	(0.11)	—	(0.12)	(0.01)	0.03	0.01	(0.10)	(0.19)	0.03	(0.04)	(0.07)	(0.01)
Weighted average shares, basic millions of shares	752	752*	707	697	695	678*	672	788	777	766*	759	755
Weighted average shares, diluted millions of shares	752	—	—	697	998	—	672	788	780	764*	759	755

Fiscal quarters (OPK's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	139	96	76	41	400	427	429	267	412	364	332	301
Accounts receivable	117	123	111	105	107	118	96	99	95	90	80	82
Inventory	69	66	59	60	59	57	64	66	65	66	64	62
Prepaid and other current assets	32	25	25	32	57	55	54	59	52	57	49	56
Total current assets	357	309	391	358	630	662	738	583	627	582	535	500
Property and equipment, net	78	75	64	67	—	70	71	75	75	74	73	71
Right-of-use asset	45	68	63	62	63	54	48	47	46	47	46	44
Goodwill	594	598	531	530	536	529	477	484	484	484	482	482
Total assets	2,057	2,012	1,974	1,980	2,256	2,200	2,128	1,973	1,996	1,932	1,857	1,829
Accounts payable	67	70	71	82	63	47	59	57	51	41	44	50
Accrued liabilities	92	90	89	95	123	118	113	91	96	84	83	78
Current portion of long-term debt	2	2	2	2	2	1	1	2	1	344	2	1
Total current liabilities	201	200	204	220	212	193	296	171	169	147	148	149
Long-term debt	8	8	4	4	4	3	3	3	3	2	2	2
Lease liability, non-current	35	54	51	50	52	49	38	37	36	37	36	34
Total liabilities	612	622	721	585	853	835	817	676	690	664	652	645
Accumulated deficit	(1,945)	(2,012)	(2,094)	(2,104)	(2,079)	(2,065)	(2,133)	(2,281)	(2,259)	(2,291)	(2,346)	(2,354)
Total stockholders' equity	1,445	1,389	1,253	1,395	1,403	1,365	1,312	1,297	1,305	1,268	1,205	1,184
Total liabilities and equity	2,057	2,012	1,974	1,980	2,256	2,200	2,128	1,973	1,996	1,932	1,857	1,829
Common shares outstanding (cover page) millions of shares	773	697	697	697	682	672	793	794	768	759	755	746

Fiscal quarters (OPK's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(84)	(66)	(82)	(10)	25	14	(68)	(148)	22	(31)	(55)	(8)
Stock-based compensation	3	3*	3	3	3	3*	3	2	3	3*	3	2
Depreciation and amortization	26	26*	26	24	24	24*	23	23	23	22*	22	22
Net cash from operating activities	33*	(38)*	(36)	(26)*	(77)*	(44)*	(35)	(83)*	(35)*	(26)*	(19)	(44)*
Net cash from investing activities	(4)*	(1)*	(4)	(7)*	248*	116*	41	(3)*	195*	(2)*	(2)	16*
Share repurchases	0*	0*	50	0*	24*	16*	0	18*	15*	14*	5	13*
Net cash from financing activities	2*	(4)*	21	(2)*	206*	(40)*	(4)	(79)*	(16)*	(18)*	(5)	(13)*
Net change in cash	31*	(43)*	(20)	(35)*	379*	26*	4	(164)*	143*	(46)*	(27)	(41)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Opko Health	301	164	(44)*	746.3M	6.9 quarters	Q2 FY26 10-Q/AJun 30, 2026
Iovance Biotherapeutics	111	99	(61)*	453.0M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Savara	42	not reported	(30)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Elite Pharmaceuticals	39	32	10	1.1B	—	Q1 FY27 10-QJun 30, 2026
Xencor	60	117	not reported	75.0M	—	Q3 FY26 10-QSep 30, 2026
Evolus	45	84	(3.6)*	66.1M	12.6 quarters	Q2 FY26 10-QJun 30, 2026
KalVista Pharmaceuticals	214	41	(14)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
Kura Oncology	70	21	(63)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Trevi Therapeutics	54	not reported	(17)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.